Valuation: Palisade Bio, Inc.

Market Cap 207M 186M 172M 156M 291M 19.75B 295M 2.06B 819M 10.34B 778M 762M 32.81B P/E 2026 *
-5.33x
P/E 2027 * -4.25x
Enterprise Value 110M 98.41M 90.98M 82.4M 154M 10.45B 156M 1.09B 433M 5.47B 412M 403M 17.35B EV / Sales 2026 *
251x
EV / Sales 2027 * -
Free-Float
95.28%
Yield 2026 *
-
Yield 2027 * -
1 day-0.83%
1 week-15.00%
Current month-11.85%
1 month-20.67%
3 months-41.09%
6 months-38.97%
Current year-49.36%
1 week 1.1
Extreme 1.1
1.37
1 month 1.1
Extreme 1.1
1.63
Current year 1.1
Extreme 1.1
2.86
1 year 1.1
Extreme 1.1
2.86
3 years 0.53
Extreme 0.53
22.35
5 years 0.53
Extreme 0.53
2,265
10 years 0.53
Extreme 0.53
8,182.5
Manager TitleAgeSince
Chief Executive Officer 68 10/10/2022
President 48 -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 67 14/02/2024
Director/Board Member 55 01/01/2019
Director/Board Member 68 02/02/2023
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 A Exercice

Chief Executive Officer

7,866,750 4.7423%
10/6/26 A Exercice

Chairperson

6,272,802 3.7814%
10/2/26 A Buy

Chairman

10,000 0.0060%
Change 5-day change 1-year change 3-year change Capi.($)
-0.83%-15.00%-35.68%-85.34% 207M
+0.65%-3.36%+36.98%+60.50% 64.14B
+1.36%+2.91%+12.50%+84.32% 55.53B
+1.22%+1.40%+12.62%+104.49% 53.03B
+2.76%+0.87%+27.92%+55.07% 45.99B
+2.00%-3.39%+17.83%+119.04% 42.45B
+1.34%-2.86%+224.43%+914.08% 40.45B
+0.64%-3.95%+11.15%+45.57% 32.25B
-1.98%+42.16%+102.96%+89.50% 34.47B
-2.72%-0.44%+23.18%-10.77% 24.23B
Average +0.42%+2.17%+43.39%+137.65% 39.27B
Weighted average by Cap. +0.82%+3.48%+49.19%+160.26%

Financials

2026 *2027 *
Net sales 438K 393K 363K 329K 614K 41.67M 621K 4.34M 1.73M 21.8M 1.64M 1.61M 69.22M -
Net income -47.56M -42.67M -39.45M -35.73M -66.75M -4.53B -67.55M -472M -188M -2.37B -178M -175M -7.52B -63.69M -57.14M -52.83M -47.84M -89.39M -6.07B -90.47M -632M -252M -3.17B -239M -234M -10.08B
Net Debt -97.7M -87.66M -81.04M -73.4M -137M -9.31B -139M -969M -386M -4.87B -367M -359M -15.46B -335M -300M -278M -251M -470M -31.88B -475M -3.32B -1.32B -16.68B -1.26B -1.23B -52.95B
Projected Income Statement - Annual - Palisade Bio, Inc.
Logo Palisade Bio, Inc.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
Employees
-
Date Price Change Volume
28/10/26 $1.190 -0.83% 15,117,654
27/10/26 $1.200 -2.44% 6,013,178
26/10/26 $1.230 -7.52% 1,704,298
23/10/26 $1.330 -1.48% 1,333,929
22/10/26 $1.350 -3.57% 1,114,138
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Palisade Bio, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
1.190USD
Average target price
9.800USD
Spread / Average Target
+723.53%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Palisade Bio, Inc.
  1. Stock Market
  2. Stocks
  3. PALI Stock